AMG319
10mM in DMSO
- Product Code: 134333
CAS:
1608125-21-8
| Molecular Weight: | 385.4 g./mol | Molecular Formula: | C₂₁H₁₆FN₇ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
AMG319 is an investigational small molecule inhibitor primarily studied for its potential in cancer immunotherapy. It targets the PI3Kδ (phosphoinositide 3-kinase delta) pathway, which plays a critical role in the activation and function of immune cells, particularly B cells and regulatory T cells (Tregs). By inhibiting PI3Kδ, AMG319 helps reduce the immunosuppressive activity of Tregs within the tumor microenvironment, thereby enhancing the body’s anti-tumor immune response.
This compound has been evaluated in clinical trials for the treatment of advanced solid tumors, with a focus on improving the efficacy of other immunotherapies such as checkpoint inhibitors. Its application is especially relevant in cancers where immune evasion is a major barrier to treatment success. Research suggests AMG319 may increase T cell infiltration into tumors and improve immune-mediated tumor cell killing.
Due to its mechanism, AMG319 holds promise as a combination therapy agent, particularly with PD-1 or PD-L1 inhibitors, to overcome resistance and boost response rates in patients with difficult-to-treat cancers. Development is ongoing to determine optimal dosing, safety, and long-term clinical benefits.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | ฿8,930.00 |
+
-
|
AMG319
AMG319 is an investigational small molecule inhibitor primarily studied for its potential in cancer immunotherapy. It targets the PI3Kδ (phosphoinositide 3-kinase delta) pathway, which plays a critical role in the activation and function of immune cells, particularly B cells and regulatory T cells (Tregs). By inhibiting PI3Kδ, AMG319 helps reduce the immunosuppressive activity of Tregs within the tumor microenvironment, thereby enhancing the body’s anti-tumor immune response.
This compound has been evaluated in clinical trials for the treatment of advanced solid tumors, with a focus on improving the efficacy of other immunotherapies such as checkpoint inhibitors. Its application is especially relevant in cancers where immune evasion is a major barrier to treatment success. Research suggests AMG319 may increase T cell infiltration into tumors and improve immune-mediated tumor cell killing.
Due to its mechanism, AMG319 holds promise as a combination therapy agent, particularly with PD-1 or PD-L1 inhibitors, to overcome resistance and boost response rates in patients with difficult-to-treat cancers. Development is ongoing to determine optimal dosing, safety, and long-term clinical benefits.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :